Product Description
Prasugrel, trade name Effient, is an investigational new antiplatelet drug currently under review for clinical use by the Food and Drug Administration. It is a thienopyridine analog with a structure similar to that of clopidogrel and ticlopidine. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18923235/)
Mechanisms of Action: P2Y12 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Acute Coronary Syndrome | Coronary Thrombosis | Myocardial Infarction | Thrombosis | Angina, Stable | Angina, Unstable
Known Adverse Events: Injuries/wounds Unspecified
Company: Cosette Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: Daiichi Sankyo
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: COVID-19|Coronary Artery Disease|Influenza, Human|Pneumonia
Phase 1: Healthy Volunteers|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023-507015-35-00 | P3 |
Unknown Status |
Coronary Artery Disease |
2031-02-28 |
|
| ANGIODAPT | P3 |
Active, not recruiting |
Coronary Artery Disease |
2029-07-21 |
|
| REMAP-CAP | P3 |
Recruiting |
Influenza, Human|COVID-19|Pneumonia |
2026-02-01 |
|
| 2006-7041-83/hah | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified|Healthy Volunteers |
2020-03-28 |